Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ESMO Annual Congress 2024

Read Scrip's analysis of the key news from the conference.

Read More

Featured Stories


An Activist Investor Makes A Play For Pfizer

Business Strategies Leadership Sales & Earnings

AstraZeneca Shows Cardiovascular Ambition With Lipoprotein Disruptor Deal

The $100m upfront deal help AZ to fill out its cardiovascular, renal and metabolism portfolio, now joining Lilly in seeking to develop an oral Lp(a)-targeting therapy.

Commercial Companies Deals

New Exacerbation Data Improves Prospects For AstraZeneca’s Airsupra

The Avillion-partnered treatment has succeeded in the BATURA trial, adding to the body of evidence supporting Airsupra as a first-in-class rescue treatment and its role in reducing the risk of asthma exacerbations in patients regardless of disease severity.

Respiratory Clinical Trials Strategy

Asia Spotlight

BIOSECURE Act: Pfizer To Lilly - Where Are The Likely Sourcing Gaps?

Lilly’s Mounjaro to Pfizer’s Paxlovid, the WuXi group has been part of pharma majors’ sourcing chain. How big is the hole clients are to fill when the proposed BIOSECURE Act comes into effect? Here’s a Scrip infographic using Evaluate Pharma data.

Commercial Policy

More coverage from Scrip's team in Asia

Scrip Podcast

Insights and perspectives on commercial, R&D, deal-making and business strategy developments.

MORE PODCASTS

 

Scrip Originals

Pipeline Watch: Eight Approvals And 11 Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Finance Watch: Biopharma IPO Queue Grows As Market Conditions Improve

Public Company Edition: Septerna, Apimeds, CAMP4 and Upstream filed paperwork with the SEC aiming to take advantage of renewed investor interest in IPOs. Also, Biohaven closed a $287.5m offering and Grifols subsidiary GigaGen obtained up to $135m from BARDA.

Financing Growth

Executives On The Move: Two New CEOs And CFOs Each And One New CMO Among This Week's Changes

Recent changes in the industry include changes at the top at Prothena and 180 Life Sciences, plus Cantargia acquires chief business officer from Ultimovacs.

Leadership Executive Changes

Deal Watch: Shionogi Will Market Nxera’s Insomnia Drug In Japan

Plus deals involving Jiangsu Alphamab/CSPC, Zydus/CDRI, Junshi/JSIAMA, Repair/Genevant, Sanofi/I-Mab, Novartis/Mitem and BioAtla/Context.

Deal Watch Business Strategies
Interviews

Judo Bio Emerges With $100m To Deliver siRNA Therapeutics To The Kidney

Judo Bio, incubated for three years by Atlas Venture to deliver siRNA and other genetic medicines to the kidney, came out of stealth mode with $100m and new CEO Rajiv Patni.

Financing StartUps and SMEs

Nxera: Building To Become Japan’s Global Biotech Champion

CEO Chris Cargill talks to Scrip about Sosei Heptares’ new identity as Nxera, the ups and downs of being big pharma’s go-to small-molecule drug hunter and its move into commercialization in Japan.

Commercial Clinical Trials

Roche’s Plan To Muscle In On Obesity

The Swiss group’s head of cardiovascular, renal and metabolism aims to speed its incretins to market, and tackle the plateauing of weight loss and muscle wastage through combinations.

Companies Clinical Trials

Pentixapharm Poised To Make A Splash In The Radiopharmaceuticals Pool

The German group is spinning off from Eckert & Ziegler and listing in Frankfurt, though a leap to the NASDAQ will likely follow once it has more data on a lymphoma theranostic.

Financing Business Strategies
See All
Graphics

BIOSECURE Act: Pfizer To Lilly - Where Are The Likely Sourcing Gaps?

Lilly’s Mounjaro to Pfizer’s Paxlovid, the WuXi group has been part of pharma majors’ sourcing chain. How big is the hole clients are to fill when the proposed BIOSECURE Act comes into effect? Here’s a Scrip infographic using Evaluate Pharma data.

Commercial Policy

Progress Or Hype? A Decade Of Cell Therapy In Japan

After 10 years of promised investment following its Nobel Prize for iPS cell research, Japan is cautiously narrowing regulations around the conditional approval of cell therapies and cutting some reimbursement prices. Commercial success remains mixed and some products have been withdrawn from the market.

Japan Policy

Obesity Rules Large-Cap Stocks In First Half Of 2024

Lilly and Novo Nordisk were top performers among large-cap pharma stocks, while the stock prices of Bristol Myers and Gilead declined the most.

Business Strategies Companies

The IPO Queue Fills Up, But A Recovery Is A Way Off

Six biopharma companies have filed to list their shares on US exchanges so far this year, but the sums they are seeking are small.

Financing Commercial
See All
Recent Stories

Viking Wins First Round In Legal Battle With Ascletis Over THRβ Agonist

The US International Trade Commission looks set to ban the importation of Ascletis's THRβ agonist into the US for use in clinical trials due to an initial legal determination on potential infringement of trade secrets related to Viking's same-class candidate VK2809.

Metabolic Disorders Legal Issues

Judo Bio Emerges With $100m To Deliver siRNA Therapeutics To The Kidney

Judo Bio, incubated for three years by Atlas Venture to deliver siRNA and other genetic medicines to the kidney, came out of stealth mode with $100m and new CEO Rajiv Patni.

Financing StartUps and SMEs

Scholar Rock Heading To Finish Line In SMA With Positive Pivotal Data

Phase III success positions Scholar Rock’s selective myostatin inhibitor for regulatory filings in early 2025. Analysts see a blockbuster opportunity for additive therapy in spinal muscular atrophy.

Clinical Trials Business Strategies

Trial Of Kezar’s Only Active Drug Halted After Five Patients Die

The FDA has placed zetomipzomib on clinical hold a year after Kezar decided to focus solely on the product.

Commercial Companies

Pipeline Watch: Eight Approvals And 11 Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Finance Watch: Biopharma IPO Queue Grows As Market Conditions Improve

Public Company Edition: Septerna, Apimeds, CAMP4 and Upstream filed paperwork with the SEC aiming to take advantage of renewed investor interest in IPOs. Also, Biohaven closed a $287.5m offering and Grifols subsidiary GigaGen obtained up to $135m from BARDA.

Financing Growth

Bristol’s Opdivo Joins Keytruda, Imfinzi In Perioperative NSCLC Treatment Space

PD-1 inhibitor Opdivo has obtained US FDA approval for pre- and post-surgical treatment in operable non-small cell lung cancer, but Merck and AstraZeneca got there first.

Approvals Business Strategies

Recordati Takes On New Debt To Fund $825m Enjaymo Buy

Once the deal with Sanofi closes, the rare disease drug will become one of Recordati’s fastest forecast sellers.

Deals Companies

Nxera: Building To Become Japan’s Global Biotech Champion

CEO Chris Cargill talks to Scrip about Sosei Heptares’ new identity as Nxera, the ups and downs of being big pharma’s go-to small-molecule drug hunter and its move into commercialization in Japan.

Commercial Clinical Trials

Gilead Seals VLs For Lenacapavir Amid Concerns Around Price, API Supplies

Gilead strikes voluntary licensing agreements with six generic manufacturers for lenacapavir but health groups seek clarity on pricing and seeming API supply restrictions. All eyes are also on the patent opposition case in India.

Commercial Business Strategies

AI/ML Alliances May Give Larger Firms Another Edge, S&P Warns

All big pharmas have proprietary artificial intelligence or machine learning platform or are partnering with third parties, according to a survey by S&P Global. Their deep pockets and early adoption are locking in a competitive advantage.

Artificial Intelligence Business Strategies

Eight Recent Deals Tapping AI/ML For R&D

Big pharmas, biotechs and the US government look to partner with artificial intelligence and machine learning firms for discovery efforts across therapeutic areas and modalities.

Deals Artificial Intelligence
UsernamePublicRestriction

Register